# Concentra Group Holdings Parent (CON) Stock Analysis: A Healthcare Play with a 28% Upside Potential

- Link: https://www.directorstalkinterviews.com/concentra-group-holdings-parent-con-stock-analysis-a-healthcare-play-with-a-28-upside-potential/4121236877
- Published: 2026-01-27T11:14:51+00:00
- Author: Madison Wilson

Investors with a keen eye on the healthcare sector may find Concentra Group Holdings
Parent (NASDAQ: CON) an intriguing opportunity. With its robust presence in the 
medical care facilities industry, Concentra offers a diversified suite of occupational
health services across the United States. Based in Addison, Texas, and with a market
capitalization of $2.84 billion, Concentra is carving a niche in providing comprehensive
occupational health solutions, including telemedicine, pharmacy distribution, and
compliance administration services.

Concentra’s current share price stands at $22.18, with a slight increase of 0.63(
0.03%) noted recently. Over the past year, the stock has fluctuated between $18.71
and $23.80, reflecting a stable trajectory within its 52-week range. This price 
stability, coupled with a promising forward P/E ratio of 14.83, suggests that Concentra
is in a healthy position to capitalize on future earnings growth.

One of the standout metrics for Concentra is its impressive revenue growth of 17.00%,
signaling strong operational performance and market demand for its services. This
is further bolstered by an exceptional Return on Equity (ROE) of 44.83%, indicating
that the company is effective in generating returns on shareholder investments. 
Additionally, Concentra boasts a free cash flow of approximately $125 million, which
provides substantial flexibility for reinvestment and strategic initiatives.

While Concentra’s dividend yield of 1.13% might not be the most compelling for income-
focused investors, the payout ratio of 21.37% indicates a sustainable dividend strategy
that leaves room for growth and reinvestment. This balance between rewarding shareholders
and fostering growth is a hallmark of a well-managed company.

Analyst sentiment towards Concentra is overwhelmingly positive, with seven buy ratings
and no hold or sell recommendations. The target price range set by analysts is between
$25.00 and $31.00, with an average target price of $28.43. This implies a potential
upside of 28.17%, making Concentra a compelling consideration for growth-oriented
investors seeking exposure in the healthcare sector.

From a technical perspective, Concentra’s 50-day and 200-day moving averages stand
at $20.13 and $20.87, respectively. The stock’s RSI (Relative Strength Index) of
37.07 suggests that it is nearing oversold territory, which could indicate a buying
opportunity for investors looking to enter at a favorable valuation. Furthermore,
the MACD (Moving Average Convergence Divergence) indicator, with a value of 0.56
against a signal line of 0.38, supports a bullish outlook in the near term.

With its origins dating back to 1979, Concentra has evolved from a subsidiary of
Select Medical Corporation to a formidable player in occupational health. Its comprehensive
offerings—from injury care to preventive health services—position it well in a sector
that is increasingly focused on holistic employee well-being and regulatory compliance.

For investors seeking a dynamic healthcare stock with growth potential and stable
financial underpinnings, Concentra Group Holdings Parent presents a compelling narrative.
The combination of strategic services, a robust financial profile, and strong market
positioning underscores its potential to deliver value to shareholders in the coming
years.

Share on:
